OPEN LABEL PHASE TWO STUDY OF ENZALUTAMIDE WITH CONCURRENT ADMINISTRATION OF RADIUM RA 223 DICHLORIDE IN CASTRATION-RESISTANT (HORMONE-REFRACTORY) PROSTATE CANCER SUBJECTS WITH SYMPTOMATIC BONE METASTASIS: